Compare Novo Nordisk A/S (NVO) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Financial Select Sector SPDR Fund — how do they compare? Novo Nordisk A/S trades at $38.38 (market cap $165.31B), while Financial Select Sector SPDR Fund trades at $54.62 (market cap $50.06B). The key difference: Novo Nordisk A/S is far larger — about 3.3× Financial Select Sector SPDR Fund's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Financial Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| NVO | XLF | |
|---|---|---|
Market Cap | $165.31B | $50.06B |
Volume | 11,432,838 | 47,464,120 |
Sector | Health | — |
52-Week High | $63.98 | $58.55 |
52-Week Low | $35.29 | $47.80 |
Typical Hold Time | 116 Days | 104 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
XLF trades at $54.48, up 1.36% with a bearish technical signal from moving averages. The ETF faces headwinds as financial stocks lag the S&P 500 by the widest margin since 1990 despite rising bank profits. Recent Fed stress test changes and interest rate hikes create both opportunities and challenges for financial sector performance.
The outlook remains cautious with technical indicators showing bearish momentum. Rising interest rates could benefit financial sector profitability, but regulatory uncertainty and market underperformance relative to broader indices present near-term risks for investors seeking financial sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
